Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT05143320 Completed - COVID-19 Clinical Trials

Cognitive, Emotional and Behavioural Impairments in Patients After Sars-Cov2 Infection

Start date: January 8, 2021
Phase:
Study type: Observational

Recent studies suggest cognitive, emotional and behavioural impairments occur in patients after SARS-CoV-2 infection. Problems with memory, attention, information processing and executive functions are particularly prevalent in these patients, probably due to hypothesised sensitivity of the hippocampus to the virus. Cognitive impairment is also present in patients with no neurological, neuropsychological and neuropsychiatric history. Therefore, the aim of the present study is to describe neuropsychological and neuropsychiatric features in patients recovered from moderate to severe forms of Covid-19 some weeks after hospital dismission.

NCT ID: NCT05142969 Not yet recruiting - Surgery Clinical Trials

Chlorhexidine Bathing to Prevent Hospital-acquired Infections: the CLEANS Study

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Hospital-acquired infections (HAI) have been shown to increase length of hospital stay and mortality. Infections acquired during a hospital stay have been shown to be preventable. The skin of patients is considered a major reservoir for pathogens associated with hospital-acquired infections, and has been suggested as a potential target for interventions to reduce bacterial burden and subsequent risk of infection. The use of daily Chlorhexidine (CHG) bathing in intensive care patients has been advocated to reduce many of the infections in critically ill patients. However, the effectiveness of CHG bathing to reduce ICU infections has varied considerably among published trials, making the effectiveness of CHG bathing in ICU patients uncertain.

NCT ID: NCT05142813 Not yet recruiting - Sepsis Clinical Trials

A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children

Start date: January 2022
Phase:
Study type: Observational

A case-control cohort study to develop and validate the performance of a whole blood gene expression test to distinguish sepsis infection from uninfected systemic inflammatory response syndrome cases in symptomatic adults and children without comorbidities.

NCT ID: NCT05142748 Completed - Clinical trials for Kidney Transplant Infection

Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital

Start date: September 1, 2019
Phase:
Study type: Observational

The investigators aimed to assess the epidemiology, management, and outcomes of community-acquired pneumonia in a kidney transplant recipients' cohort and identify prognosis factors associated with in-hospital complications. The investigatorsintend to identify each stay by a national database. Then they will be consulted by 2 clinicians to assert CAP clinical definition. After that radiographic evidence will be reviewed to validate CAP diagnoses. Then clinical data are collected in each center.

NCT ID: NCT05141188 Not yet recruiting - Clinical trials for Urinary Tract Infections

Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections

Start date: December 1, 2021
Phase:
Study type: Observational

Urinary tract infection is among the most common nosocomial and community acquired infections. The Information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy .Resistance to antibiotic treatment in patients with urinary tract infections (UTIs) is a representative example of the increasing problem of antimicrobial resistance. Extended-spectrum β-lactamases (ESBLs) has emerged as an important mechanism of resistance in Gram-negative bacteria.

NCT ID: NCT05141058 Recruiting - Clinical trials for SARS-CoV-2 Infection

T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS

TONI
Start date: October 19, 2021
Phase: Phase 1
Study type: Interventional

This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and <4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and <80 years) HSCT recipients (Arm A) and pediatric (≥12 years of age and <18 years) HSCT recipients (Arm B), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity.

NCT ID: NCT05140187 Recruiting - Clinical trials for CMV Infection After Allogenic HSCT

CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

Start date: October 15, 2021
Phase: Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after allogenic HSCT.

NCT ID: NCT05139628 Not yet recruiting - Clinical trials for Catheter-Related Infections

Peripheral Venous Catheter Related Blood Stream Infections

Start date: December 1, 2021
Phase:
Study type: Observational

The aim of this work is to: 1. Study the impact of PIVC skin colonization on catheter tip colonization and the development of CRBSI 2. isolate and identify the organisms causing peripheral venous catheter related blood stream infections in pediatric oncology patients. 3. perform antimicrobial sensitivity testing of isolated organisms. 4. identify the associated risk factors that lead to CRBSIs in such group of patients.

NCT ID: NCT05139524 Recruiting - Rift Valley Fever Clinical Trials

RVF and Other Emerging Infectious Diseases in East and Central Africa

Start date: October 8, 2021
Phase:
Study type: Observational

Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo

NCT ID: NCT05138822 Not yet recruiting - Clinical trials for Uncomplicated Urinary Tract Infections

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Start date: December 7, 2021
Phase: Phase 1
Study type: Interventional

This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response following daily oral dosing for 5 days of GSK3882347 in an adult female with uncomplicated urinary tract infections (uUTI). Comparator nitrofurantoin will be included in the study to ensure unbiased reporting of safety events. The study will be separated into 2 cohorts. Cohort 1 consists of an inpatient treatment period and PK analysis at frequent timepoints. Cohort 2 includes an outpatient treatment period and PK analysis conducted less frequently, at key trough timepoints.